INCY Quote, Financials, Valuation and Earnings

Exelixis has a net margin of 9.36% compared to Incyte's net margin of 21.87%. Incyte's return on equity of 0.75% beat Exelixis's return on equity of 20.97%.

Incyte has a consensus price target of $79.38, signalling upside risk potential of 13.55%. On the other hand Exelixis has an analysts' consensus of $33.38 which suggests that it could fall by -1.3%. Given that Incyte has higher upside potential than Exelixis, analysts believe Incyte is more attractive than Exelixis.

Incyte has a beta of 0.686, which suggesting that the stock is 31.381% less volatile than S&P 500. In comparison Exelixis has a beta of 0.518, suggesting its less volatile than the S&P 500 by 48.162%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Exelixis pays out -- of its earnings as a dividend.

Incyte quarterly revenues are $1.1B, which are larger than Exelixis quarterly revenues of $539.5M. Incyte's net income of $106.5M is lower than Exelixis's net income of $118M. Notably, Incyte's price-to-earnings ratio is 499.36x while Exelixis's PE ratio is 21.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.72x versus 4.89x for Exelixis. Usually stocks with elevated PS ratios are considered overvalued.

Insmed has a net margin of 9.36% compared to Incyte's net margin of -236.04%. Incyte's return on equity of 0.75% beat Insmed's return on equity of --.

Incyte has a consensus price target of $79.38, signalling upside risk potential of 13.55%. On the other hand Insmed has an analysts' consensus of -- which suggests that it could grow by 26.75%. Given that Insmed has higher upside potential than Incyte, analysts believe Insmed is more attractive than Incyte.

Incyte has a beta of 0.686, which suggesting that the stock is 31.381% less volatile than S&P 500. In comparison Insmed has a beta of 1.103, suggesting its more volatile than the S&P 500 by 10.328%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

Incyte quarterly revenues are $1.1B, which are larger than Insmed quarterly revenues of $93.4M. Incyte's net income of $106.5M is higher than Insmed's net income of -$220.5M. Notably, Incyte's price-to-earnings ratio is 499.36x while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.72x versus 31.97x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 9.36% compared to Incyte's net margin of 25.23%. Incyte's return on equity of 0.75% beat Pfizer's return on equity of 4.63%.

Incyte has a consensus price target of $79.38, signalling upside risk potential of 13.55%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.16%. Given that Pfizer has higher upside potential than Incyte, analysts believe Pfizer is more attractive than Incyte.

Incyte has a beta of 0.686, which suggesting that the stock is 31.381% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.28% to investors and pays a quarterly dividend of $0.42 per share. Incyte pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Incyte quarterly revenues are $1.1B, which are smaller than Pfizer quarterly revenues of $17.7B. Incyte's net income of $106.5M is lower than Pfizer's net income of $4.5B. Notably, Incyte's price-to-earnings ratio is 499.36x while Pfizer's PE ratio is 36.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.72x versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of 9.36% compared to Incyte's net margin of -788.06%. Incyte's return on equity of 0.75% beat Sage Therapeutics's return on equity of -48.2%.

Incyte has a consensus price target of $79.38, signalling upside risk potential of 13.55%. On the other hand Sage Therapeutics has an analysts' consensus of $24.39 which suggests that it could grow by 64.23%. Given that Sage Therapeutics has higher upside potential than Incyte, analysts believe Sage Therapeutics is more attractive than Incyte.

Incyte has a beta of 0.686, which suggesting that the stock is 31.381% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.067%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Incyte quarterly revenues are $1.1B, which are larger than Sage Therapeutics quarterly revenues of $11.9M. Incyte's net income of $106.5M is higher than Sage Therapeutics's net income of -$93.6M. Notably, Incyte's price-to-earnings ratio is 499.36x while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.72x versus 3.11x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.